11 Results for "

Suv39h2

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "Suv39h2" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-122181
CAS No.: 2093400-18-9
Purity:  98.55%
Research Areas:  

Cancer

OTS186935 is a potent protein methyltransferase SUV39H2 inhibitor with an IC50 of 6.49 nM. OTS186935 shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS193320 regulates the production of γ-H2AX in cancer cells .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-122181B
Purity:  99.58%
Research Areas:  

Cancer

OTS186935 hydrochloride is a potent protein methyltransferase SUV39H2 inhibitor with an IC50 of 6.49 nM. OTS186935 hydrochloride shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS193320 hydrochloride regulates the production of γ-H2AX in cancer cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-13807
CAS No.: 1320288-17-2
Purity:  99.38%
Research Areas:  

Cancer

UNC0646 is a potent and selective histone methyltransferase G9a inhibitor with an IC50 of 6 nM. UNC0646 is also a potent GLP inhibitor (IC50 <15 nM) and highly selective for G9a/GLP over SETD7, SUV39H2, SETD8 and PRMT3. UNC0646 reduces H3K9me2 levels in MDA-MB-231 cells with an IC50 of 26 nM .
loading...
    loading...
Cat. No.: HY-122182
CAS No.: 2093401-33-1
Purity:  98.64%
Research Areas:  

Cancer

OTS193320, a imidazo[1,2-a]pyridine compound, is a SUV39H2 methyltransferase activity inhibitor. OTS193320 decreases global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggers apoptotic cell death. Combination of OTS193320 with Doxorubicin (HY-15142A) results in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX .
loading...
    loading...
Cat. No.: HY-RS14052
Research Areas:  

Others

SUV39H2 Human Pre-designed siRNA Set A contains three designed siRNAs for SUV39H2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS18319
Research Areas:  

Others

Suv39h2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Suv39h2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS24797
Research Areas:  

Others

Suv39h2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Suv39h2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-122181A
CAS No.: 2093401-85-3
Research Areas:  

Cancer

OTS186935 trihydrochloride is a protein methyltransferase SUV39H2 inhibitor with an IC50 of 6.49 nM. OTS186935 trihydrochloride shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS186935 trihydrochloride regulates the production of γ-H2AX in cancer cells .
loading...
    loading...
Cat. No.: HY-P82137
Synonyms: H3 K9 HMTase 2; KMT1B; Su(var)3 9 homolog 2; Suv39h2

Host:  

Rabbit

Application:  

WB, IHC-P, IP

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Cat. No.: HY-185849
CAS No.: 2585194-96-1
Research Areas:  

Cancer

SETDB1-IN-1 is a SETDB1 inhibitor with an IC50 of 16 μM. SETDB1-IN-1 inhibits histone methyltransferase) activity via SAM-competitive and peptide-dependent mechanisms. SETDB1-IN-1 is applicable to research related to melanoma, lung cancer, liver cancer, breast cancer and prostate cancer .
loading...
    loading...
Cat. No.: HY-13689G
CAS No.: 133053-19-7
Go 6983 GMP is Go 6983 (HY-13689) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Go 6983 is a dual inhibitor targeting Suv39h1/2 (KMT1A/KMT1B) and PKC, as well as a transcriptional activator capable of inducing DNA hypomethylation. Go 6983 stimulates the transcription of Prdm14 by reducing Suv39h1/2 protein levels, decreasing histone modifications in the Prdm14 promoter region, and increasing the recruitment of RNA polymerase II. Go 6983 induces genome-wide DNA hypomethylation by inhibiting de novo methyltransferase expression and increasing Tet1/Tet2 levels, thereby promoting self-renewal and pluripotency maintenance of stem cells. Meanwhile, Go 6983 can block PKC-mediated signaling pathways to reduce the expression of EMT-related genes and eliminate the upregulation of antioxidant genes downstream of NRF2. Go 6983 is mainly used in mechanism studies related to myocardial ischemia/reperfusion injury .
loading...
    loading...
  • 1